NEW YORK (Reuters Health) – in einer kleinen Studie der Phase<\/p>\n
II, Tremelimumab Medikament schien f\u00fcr Patienten “vielversprechend”<\/p>\n
mit Hepatitis C<\/span> und fortgeschrittenen hepatozellul\u00e4ren Karzinom: in einigen<\/p>\n F\u00e4llen stabilisiert Krankheit seit mehr als einem Jahr, je nach<\/p>\n best\u00e4tigt die Autoren in Chicago w\u00e4hrend der Jahrestagung<\/p>\n Der American Association f\u00fcr die Forschung von Krebs.<\/p>\n Tremelimumab ist ein menschlicher monoklonaler Antik\u00f6rper<\/span>, die bindet<\/p>\n CTLA-4 ausgedr\u00fcckt auf der Oberfl\u00e4che der aktivierten T-Zellen.<\/p>\n hemmt, die Deregulierung der Aktivierung von T-Zellen<\/p>\n vermittelten B7-CTLA – 4, wie Sie von Dr. Ignacio Melero<\/span>,<\/p>\n Zentrum Forschung medizinische angewendet an der University of<\/p>\n Navarra in Pamplona, Spanien.<\/p>\n “We knew that cells in hepatic infiltrates of<\/p>\n hepatocellular carcinoma and patients<\/span> with the virus of the<\/p>\n chronic hepatitis C Express CTLA-4, which is the target of this<\/p>\n monoclonal antibody”, said Melero to Reuters Health.<\/p>\n “there is also a prior experience on the possible<\/p>\n immunogenicity of carcinoma cells hepatocellular. Lo<\/p>\n more interesting for us was to have been able to study the<\/p>\n effects in a tumor target and a viral at the same white<\/p>\n time”, added the expert.<\/p>\n Melero team assessed 20 patients treated with<\/p>\n tremelimumab intravenously (15 mg\/kg every 90 days) during<\/p>\n an average of two cycles (between one and four). patients<\/p>\n they had around 68 years old and 71 per cent were men.<\/p>\n two patients responded partially and 11 had<\/p>\n illnessd Estable. de M\u00e1s del 33 Por Ciento de Los Pacientes<\/p>\n la Estabilidad Dur\u00f3 M\u00e1s de 12 Meses.<\/p>\n La Supervivencia allgemeinen Durchschnitt Fue de 7,5 Meses y el<\/p>\n Tiempo Hasta la Progresi\u00f3n De La Enfermedad, Meses de 6,4, Seg\u00fan<\/p>\n Informaron Los Investigadores Durante la Conferencia.<\/p>\n Melero Se\u00f1al\u00f3 Que el Tratamiento Fue “Muy Bien Tolerado, de<\/p>\n Allgemeine”.<\/p>\n El 80 Por Ciento de Los Pacientes Tuvieron Efectos Adversos<\/p>\n Asociados con el F\u00e1rmaco.<\/p>\n Lo M\u00e1s Frecuente Fue el Prurito Leve ein Moderado (Por el 40<\/p>\n Ciento), Picaz\u00f3n (el 45 Por Ciento), Niveles de Transaminasa<\/p>\n Elevados (el 30 Por Ciento), Fatiga (el 20 Por Ciento) Diarrea<\/p>\n (el 10 Por Ciento), Constipaci\u00f3n (el 10 Por Ciento) y Magersucht<\/p>\n (el 10 por ciento). kein Se Registraron Efectos Secundarios<\/p>\n Potencialmente Fatales.<\/p>\n El Equipo Tambi\u00e9n Observ\u00f3 Una Reducci\u00f3n De La Carga del<\/p>\n < p> virus of hepatitis C in the blood of patients, along with<\/p>\n an increase of the immunity that viral load reduction<\/p>\n was associated with an increase in the response immune against the<\/p>\n virus in 76 percent of the patients.<\/p>\n Melero said that tremelimumab could also be used in<\/p>\n patients with chronic infection by hepatitis c virus<\/p>\n could, perhaps, prevent or delay the onset of cancer<\/p>\n liver.<\/p>\n “treat the virus of hepatitis C in a person with cancer<\/p>\n liver makes no sense because the virus caused already its biggest<\/p>\n damage, but there is the possibility of complementing the therapies<\/p>\n against the virus with CTLA-4 monoclonal antibodies”, said to<\/p>\n Reuters Health.<\/p>\n Ruth I have, from the Centre of Oncology Lombardi, Dr. of the<\/p>\n Georgetown University, in Washington, considered that it is still<\/p>\n too fr\u00fch, um zu einem endg\u00fcltigen Schluss mit diesem<\/p>\n Studio klein.<\/p>\n jedoch gesagt: “diese Forschung<\/p>\n Molek\u00fcl sollte setzen Sie fort. ist eine einzigartige Verbindung, weil<\/p>\n Acts auf Toleranz immun gegen den Tumor ist eine neue<\/p>\n Art der Therapie”.<\/p>\n Pfizer finanziert die Studie und MedImmune entwickelt<\/p>\n Tremelimumab.<\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK (Reuters Health) – in einer kleinen Studie der Phase II, Tremelimumab Medikament schien f\u00fcr Patienten “vielversprechend” mit Hepatitis C und fortgeschrittenen hepatozellul\u00e4ren Karzinom: in einigen F\u00e4llen stabilisiert Krankheit seit mehr als einem Jahr, je nach best\u00e4tigt die Autoren in Chicago w\u00e4hrend der Jahrestagung Der American Association f\u00fcr die Forschung von Krebs. Tremelimumab ist […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-30414","post","type-post","status-publish","format-standard","hentry","category-allgemeine","et-doesnt-have-format-content","et_post_format-et-post-format-standard"],"_links":{"self":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/30414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/comments?post=30414"}],"version-history":[{"count":0,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/30414\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/media?parent=30414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/categories?post=30414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/tags?post=30414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}